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P-value
Poster Session-II 117was 51 (range, 18–67) y., with 46 (54%) female donors, 33 (39%)
myeloid malignancies, 49 (58%) lymphoid malignancies, and 3
cases of SAA. The stem cell source was PBSC in 66 (78%) pa-
tients, while BM was used in 19 (22%) patients. 37 (43.5%)
were transplanted from a matched related donor, and 48
(56.5%) from a matched unrelated donor. A myeloablative condi-
tioning regimen was used in 24 (28%) patients, and 61 (72%) re-
ceived a reduced intensity regimen. The median concentrations of
CsA in the blood at 1, 2, 3 and 4 weeks after allo-SCT were 348
(range, 172–733), 284 (range, 137–535), 274 (range, 107–649), and
247 (37–695) ng/mL respectively. All patients engrafted at a me-
dian of 17 (range, 0–42) days after allo-SCT. With a median fol-
low-up of 16 (range, 5–29) months, grade 2–4 acute GVHD
occurred in 36 patients (42%) at a median of 29 (range, 6–100)
days after allo-SCT. The incidence of severe grade 3–4 acute
GVHD was 23% (95%CI, 14–32%). In multivariate analysis, we
found that higher whole-blood CsA concentration in the first
week following graft infusion, and before onset of acute GVHD
was the strongest parameter significantly associated with a reduced
the risk of severe grade 3–4 acute GVHD (P 5 0.01; RR 5 0.24;
95%CI, 0.08–0.73). This data indicates a close relationship be-
tween CsA trough blood concentration during the early post
allo-SCT period and the severity of acute GVHD. Inadequate
or insufficient early exposures to CsA can be a serious risk for de-
veloping severe acute GVHD. Therefore, precise monitoring of
CsA concentrations and achievement of a high CsA target concen-
tration may be an effective tool to prevent the onset of severe
acute GVHD.326
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We previously reported that rituximab was associated with a re-
duced incidence of acute graft versus host disease (GVHD) when in-
corporated into a standard transplant preparative regimen for ALL.
To confirm our findings, we conducted a randomized, prospective
study.
Methods: Adult ALL pts received a standard myeloablative con-
ditioning regimen of total body irradiation (TBI, 12 Gy in four daily
fractions) followed by etoposide 60 mg/kg  1 dose with allogeneic
HSCT. Rituximab was administered at 375 mg/m2 on days27,21,
17 and 114 following stem cell infusion in pts randomized to re-
ceive the drug. GVHD prophylaxis consisted of tacrolimus and
mini-dose methotrexate for all pts, and anti-thymocyte-globulin
was added to matched unrelated pts. Palifermin to reduce the inci-
dence of mucositis was administered to all pts. The first 20 pts
were randomized equally to the possibility of receiving rituximab,
with subsequent randomization based on a Bayesian adaptive algo-
rithm.
Results: Twenty-one pts have been entered onto study. Patient
characteristics and treatment outcomes are detailed in Table 1. Of
note, there were greater numbers of pts with disease beyond CR1
in the rituximab group. There was no significant difference between
the 2 treatment groups with respect to the incidence of acute
GVHD; 3 pts in the rituximab group developed chronic extensive
GVHD. Seven of 10 (70%) pts on the rituximab treatment arm
have died with a median time to death of 6.9 months: relapse n 5
4, infection n 5 2, organ failure n 5 1; no pts on the standard treat-
ment arm have died with a median follow-up of 14 months (range
3–32 months). Overall survival for the rituximab group was signifi-
cantly worse at 30% versus 100% for the standard treatment arm,
p 5 0.005. Four of 10 (40%) pts on the rituximab treatment arm
have had progressive disease, and all 4 of these pts died. Only 1 of
11 (9%) pts on the standard treatment arm had progressive disease
at 14.5 months after HSCT and remains alive at 17.6 months after
HSCT. In conclusion, our results demonstrate that the addition ofrituximab to the standard etoposide and TBI conditioning regimen
for allogeneic HSCT in ALL does not impact GVHD. Furthermore,
rituximab appears to negatively impact survival, with increased risk
of disease relapse. However, the small sample size and greater num-
bers of pts with advanced disease in the rituximab arm limit these
conclusions.
Table 1. Patient Characteristics and Treatment Results
Etoposide/ Etoposide/
TBI TBI/RituximabNo. pts No. ptsTotal Treated 11 10
Median Recipient
Age in Years (range)33 (20247) 32 (19252) 0.382Gender (%): 0.999
Female 3 (27) 3 (30)
Male 8 (73) 7 (70)
Diagnosis Status (%) 0.158
CR1 7 (64) 3 (30)
CR2 4 (36) 3 (30)
Beyond CR2 0 (0) 1 (10)
Relapse 0 (0) 3 (30)
Histology (%): 0.035
T-cell 0 (0) 4 (40)
B-cell 11 (100) 6 (60)
Ph1 (%) 0.311
No 7 (64) 9 (90)
Yes 4 (36) 1 (10)
Donor Type (%) 0.387
Matched related 6 (55) 3 (30)
Matched unrelated 5 (45) 7 (70)
Stem Cell Source (%)* 0.008
Bone marrow 3 (27) 9 (90)
Peripheral blood 8 (73) 1 (10)
Acute GVHD (%) 0.999
Grades II-IV 3 (27) 9 (90)
Grades III-IV 0 0
Chronic Extensive GVHD (%) 0 3 (33) 0.090
Overall Survival 100% 30% 0.005
Progression-Free Survival 90% 60% 0.009327
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Activated natural killer (NK) cells derived from cord blood (CB)
have been reported to mediate a significant graft versus leukemia ef-
fect (GVL). However unmanipulated CB NK cells exhibit poor cy-
tolytic activity against tumor cells in vitro, thus limiting their
clinical application. We investigated the mechanism for the poor
cytolytic activity of CB NK cells and whether the defect can be
overcome with ex vivo expansion. NK cell killing of the tumor tar-
get cells is achieved by the formation of a mature immune synapse,
followed by secretion of lytic granules containing perforin and
granzymes. We hypothesized that CB NK cells exhibit low cytotox-
icity against leukemia blasts due to a defect in the formation of the
immune synapse. We have found reduced ability of CB NK cells to
form immune synapses with leukemia target cells contributing to
the decreased cytotoxicity of unmanipulated CB NK cells com-
pared to adult peripheral blood (APB) NK cells. F-actin polariza-
tion was observed in a mean of 12% (range 9–21%) of the CB
NK cell/tumor cell conjugates versus a mean of 85% (range 68–
87) of APB NK/tumor conjugates (p\ 0.001). This impairment
could then be reversed by ex vivo expansion of CB NK cells with
